Linker Strategies in Antibody-Drug Conjugates: Insights from HER2-Targeted ADCs
DOI:
https://doi.org/10.54097/9j82fa18Keywords:
HER2, ADC, linker, cyclopropyl, trastuzumab.Abstract
In tumors with alterations of human epidermal growth factor receptor 2 (HER2), conventional monoclonal antibodies and tyrosine kinase inhibitors (TKIs) are limited by intratumoral heterogeneity and acquired resistance. Antibody-drug conjugates (ADCs) take advantage of the selectivity of monoclonal antibodies to deliver highly efficient cytotoxins and rely on linkers to achieve spatiotemporal controlled release. Representative HER2-targeted ADCs can be roughly divided into three examples. The first is trastuzumab emtansine (T-DM1), which uses a non-cleavable linker to attach the maytansinoid DM1. The second example is trastuzumab drutecan (T-DXd), which uses the Gly-Gly-Phe-Gly cleavable linker for conjugation with topoisomerase I inhibitors (DXd). Recently, SHR-A1811 introduced a payload carrying a chiral cyclopropyl group, which provided different stability. These improvements enable the drug to be released more controllably within tumor cells and expand the indications from patients with high HER2 expression to those with low HER2 expression or even HER2 mutations. Among these drugs, the linker is no longer merely a simple "bridge"; it also determines the degree of exposure to the load, the way the drug is released in the body, and even affects the toxicity that patients may face. This review summarizes the development of HER2-targeted ADCs, with a focus on the evolution of linker strategies and their impact on efficacy and safety, with the aim of providing ideas for the future design of HER2-targeted ADCs.
Downloads
References
[1] Ehrlich P. Address in pathology, on chemotherapy: delivered before the seventeenth international congress of medicine. British Medical Journal, 1913, 2 (2746): 353-359.
[2] Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody–drug conjugates. Nature Reviews Drug Discovery, 2017, 16 (5): 315-337.
[3] Chari R V J, Miller M L, Widdison W C, et al. Antibody–drug conjugates: an emerging concept in cancer therapy. Angewandte Chemie International Edition, 2014, 53 (15): 3796-3827.
[4] Bargh J D, Isidro-Llobet A, Parker J S, et al. Cleavable linkers in antibody–drug conjugates. Chemical Society Reviews, 2019, 48 (16): 4361-4374.
[5] Tsuchikama K, An Z. Antibody–drug conjugates: recent advances in conjugation and linker chemistries. Protein & Cell, 2018, 9 (1): 33-46.
[6] Chau C H, Steeg P S, Figg W D, et al. Antibody–drug conjugates for cancer. The Lancet, 2019, 394 (10200): 793-804.
[7] Moasser M M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene, 2007, 26 (45): 6469-6487.
[8] Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clinical Cancer Research, 2016, 22 (20): 5097-5108.
[9] Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 2012, 367 (19): 1783-1791.
[10] Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. New England Journal of Medicine, 2020, 382 (7): 610-621.
[11] NMPA approves Hengrui Pharma’s trastuzumab rezetecan for HER2-mutant NSCLC. Precision Medicine Online, 2025-05-29. Accessed 2025-08-27.
[12] Yarden Y, Sliwkowski M X. Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2001, 2 (2): 127-137.
[13] Arteaga C L, Engelman J A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell, 2014, 25 (3): 282-303.
[14] Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235 (4785): 177-182.
[15] Wolff A C, Hammond M E H, Allison K H, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Journal of Clinical Oncology, 2018, 36 (20): 2105-2122.
[16] Tarantino P, Hamilton E, Tolaney S M, et al. HER2-low breast cancer: pathological and clinical landscape. Journal of Clinical Oncology, 2020, 38 (17): 1951-1962.
[17] Li B T, Ross D S, Aisner D L, et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. Journal of Thoracic Oncology, 2016, 11 (3): 414-419.
[18] Robichaux J P, Elamin Y Y, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer. Nature Medicine, 2018, 24 (5): 638-646.
[19] Tarantino P, Morganti S, Curigliano G, et al. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Exploration of Targeted Anti-tumor Therapy, 2021-03-23.
[20] Swain S M, Shastry M, Hamilton E, et al. Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery, 2023, 22 (2): 101-126.
[21] Zhang T, Xu J, Yin J, et al. SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. PLOS ONE, 2025, 20 (6): e0326691.
[22] Chia C S B. A patent review on FDA-approved antibody-drug conjugates, their linkers and drug payloads. ChemMedChem, 2022, 17 (11): e202200032.
[23] Chen L, Wang L, Shion H, et al. In-depth structural characterization of Kadcyla (ado-trastuzumab emtansine) and its biosimilar candidate. mAbs, 2016, 8 (7): 1210-1223.
[24] Ou J, Si Y, Goh K, et al. Bioprocess development of antibody-drug conjugate production for cancer treatment. PLOS ONE, 2018, 13 (10): e0206246.
[25] Jain N, Smith S W, Ghone S, et al. Current ADC linker chemistry. Pharmaceutical Research, 2015, 32 (11): 3526-3540.
[26] Wang R, Hu B, Pan Z, et al. Antibody–drug conjugates (ADCs): current and future biopharmaceuticals. Journal of Hematology & Oncology, 2025, 18 (1): 51.
[27] Lu D, Girish S, Gao Y, et al. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemotherapy and Pharmacology, 2014, 74 (2): 399-410.
[28] Tan X, Fang P, Li K, et al. A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells. mAbs, 2023, 15 (1): 2220466.
[29] Jang J Y, Kim D, Lee N K, et al. Antibody–drug conjugates powered by deruxtecan: innovations and challenges in oncology. International Journal of Molecular Sciences, 2025, 26 (13): 6523.
[30] Miller J T, Tumey L N. ADC linkers strategies for the release of alcohol-containing payloads. In: Van Delft F, Lambert J M, eds. Chemical Linkers in Antibody–Drug Conjugates (ADCs). The Royal Society of Chemistry, 2021, 7: 232-262.
[31] Balamkundu S, Liu C F, et al. Lysosomal cleavable peptide linkers in antibody–drug conjugates. Biomedicines, 2023, 11 (11): 3080.
[32] Walsh S J, Bargh J D, Dannheim F M, et al. Site-selective modification strategies in antibody–drug conjugates. Chemical Society Reviews, 2021, 50 (2): 1305-1353.
[33] SHR-A1811 maintains efficacy, safety in pretreated HER2-expressing or mutated breast cancer and other solid tumors. OncLive, 2025-01-22. Accessed 2025-08-27.
[34] Sun M R, Li H L, Ba M Y, et al. Cyclopropyl scaffold: a generalist for marketed drugs. Mini-Reviews in Medicinal Chemistry, 2021, 21 (2): 150-170.
[35] Meanwell N A. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chemical Research in Toxicology, 2011, 24 (9): 1420-1456.
[36] Rakhmanina N Y, Van Den Anker J N. Efavirenz in the therapy of HIV infection. Expert Opinion on Drug Metabolism & Toxicology, 2010, 6 (1): 95-103.
[37] Lovering F, Bikker J, Humblet C, et al. Escape from flatland: increasing saturation as an approach to improving clinical success. Journal of Medicinal Chemistry, 2009, 52 (21): 6752-6756.
[38] Wermuth C G, Aldous D, Raboisson P, et al. The Practice of Medicinal Chemistry: Index, 2015.
[39] Cazzamalli S, Dal Corso A, Neri D, et al. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma. Journal of Controlled Release, 2017, 246: 39-45.
[40] Trail P A, Dubowchik G M, Lowinger T B, et al. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. Pharmacology & Therapeutics, 2018, 181: 126-142.
[41] Thomas A, Teicher B A, Hassan R, et al. Antibody–drug conjugates for cancer therapy. The Lancet Oncology, 2016, 17 (6): e254-e262.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
